AB-Biotics, a CataloniaBio & HealthTech member company, has closed a deal with the Japan-based Kaneka...

Vytrus Biotech, a CataloniaBio & HealthTech member company, has successfully closed the €1-million round...

Devicare and nine leading hospitals in urology have started the pioneering international "Double J" study to...

Grifols, member of CataloniaBio & HealthTech, makes inroads in its research efforts to find a treatment for Alzheimer...

Pharmaphenix, member of CataloniaBio & HealthTech and headquartered in the Barcelona Science Park, is celebrating...

Archivel Farma, owner of the therapeutic vaccine targeting tuberculosis Ruti®, and Laboratorios Silanes, one of the major Mexican pharmaceutical companies, have signed a collaboration agreement for the clinical development and commercialization of the vaccine in Mexico.

The pharmaceutical company Reig Jofre strengthens its commitment to open innovation and the development of injectable and freeze-dried products with the creation of the joint venture Syna Therapeutics, for the development of biopharmaceutical products in the field of biosimilar products and innovative molecules.

Mario Rovirosa has been named CEO of pharmaceutical company Ferrer and will take up this position on 1 April. Rovirosa is taking over for Jordi Ramentol that will continue to have ties to Ferrer as a member of the company’s board of directors.  

Una setantena d'emprenedors i professionals de l'àmbit de la biomedicina i la salut van participar a la jornada sobre les oportunitats internacionals en compra pública d’innovació (CPI) organitzada per ACCIÓ i CataloniaBio & HealthTech, el dia 6 de març a Barcelona.

The latest edition of the Fem Talent Fòrum recognised Dr Judit Anido, CEO of Mosaic Biomedicals and member of the board at CataloniaBio & HealthTech, in the emerging talent category. Anido is the co-founder, with Dr Joan Seoane and Dr Josep Baselga, of Barcelona-based biotechnology firm Mosaic Biomedicals, which is developing personalised cancer treatments. 

Another company in the biomedicine and healthcare arena, ProteoDesign, was a runner-up in the organisation category. The awards were given out in a ceremony held at Barcelona Activa Advanced Industry Park with more than 400 people in attendance. The Fem Talent awards aim to recognise ...

Biotechnology company Thrombotargets has opened a round of funding looking to raise €5.5 million to complete development of its topical treatment for haemorrhages during surgery. The drug, known as TT-173, has begun phase III clinical trials. The Castelldefels-based company has been working on this product for 15 years now.

The main shareholder in Thrombotargets is Biotech Angels and the chairman of the board of directors is perfume businessman Ramón Béjar. The board of directors  is formed by Ignasi Miquel, Pilar Sánchez i Jesús Murat. The company was started in 2005, developing the BioplatformScreen platform used to screen molecules.  ...

Yesterday, CataloniaBio & HealthTech awarded the 2018 Biosuccess Award recognising the most important business milestones in biomedicine and health in Catalonia to Anaconda Biomed and Mind the Byte. 

The pharmaceutical corporation Reig Jofre has closed out 2017 with net profits of €8.8 million, up 14.9% from the previous year

Xavier Luria is the new partner and strategy advisor of FreeOx Biotech, in a bid to accelerate development and the regulatory process for its main drug candidate, Ox-01, to treat stroke.

Luria, linked to CataloniaBio & HealthTech, is a world-renowned expert in clinical and regulatory drug development. Since 2012, he has been an independent senior consultant in Drug Development and Regulation (DDR) with offices in Barcelona and London. He was head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA) from 2005 to 2012.

Xavier Luria highlights: “Given its advanced stage of development, Ox-01 could become a ...

El Parc Científic de Barcelona (PCB) presenta el programa MedTeX especialitzat en l'acceleració d'empreses de recent creació en l'àmbit de les tecnologies mèdiques. En total acollirà 12 empreses, de forma gratuïta, i el termini per poder-hi optar acaba el 30 de març de 2018. 

MedTeX és una oportunitat perquè els emprenedors treballin amb referents del sector per impulsar les seves empreses i assolir els objectius a través de la formació, elmentoring i el networking en l'entorn privilegiat del PCB. El PCB té una experiència acumulada de 30 empreses incubades.

El programa compta amb ...

Biotechnology firm Pangaea Oncology has signed a new contract with German multinational corporation Merck, with a capital injection of more than €260,000. Specifically, Pangaea will conduct several in vitro experiments and analyse the prevalence of various genes of interest to Merck that are associated with drugs the company has in the clinical development phase. The aim is to find drug-use strategies for several subtypes of breast and lung cancer, under what is known as biomarker discovery.

Pangaea will give Merck access to its latest-generation laboratory and data-analysis capabilities to measure the prevalence in patients at its subsidiary, Dr Rosell ...

ProteoDesign, a biotech spin-out from Princeton University and University of Barcelona and member of CataloniaBio & HealthTech, has raised a financing round of 1.7 million euros led by existing investor Caixa Capital Risc and joined by an undisclosed private investor.

The company is developing personalized immunological treatments against cancer through patented technology discovered after more than 20 years of pioneering research in this field. The funds obtained will be used to advance candidates for drugs in the preclinical phase.

Dr. Miquel Vila Perelló, CEO of ProteoDesign, explained in this interview by CataloniaBio & HealthTech that "the conjugated antibodies are ...

The Business Council of the Vall d'Hebron Research Institute (VHIR), which includes CataloniaBIO members, met for the second time on 25 January. This board advises the VHIR directors and trustees, helping them identify opportunities, participate in joint projects and facilitate access to public and private resources.

The board has 15 members from finance, business and biotechnology, including companies and organisations such as Asebio, Fenin, Specific Pig, Grup Ferrer, ”la Caixa” Banking Foundation, AMETIC, Roche Diagnostics, Banco Sabadell, Laboratoris Esteve and Biocat. The board was created two years ago and is chaired by Lluís Bassat. 

The VHIR management team presented ...

Oryzon Genomics has announced changes on its corporate governing bodies. The company has incorporated to its Board of Directors Dr. José Carlos Gutiérrez-Ramos, president and CEO of Synlogic Inc. (SYBX, NASDAQ) as independent director. Dr. Gutiérrez-Ramos is a key addition for the company in its expansion plans in the US market. 

Between 2009-2015, he was group senior vicepresident at Pfizer and head of its research center in Cambridge/Boston. In his current role as founder and CEO of Synlogic he has raised more than 200 million dollars with the participation of specialized investment funds.

In the same meeting of ...

The Hospital Clínic of Barcelona has launched PortalCLINIC, a website with proven and reliable information on health, in order to combat access to health information that is not very reliable, or even alarmist, that people find on the Internet. The content is supported by more than 200 medical and nursing professionals from the centre.

Dr. Antoni Castells, medical director of the centre, is one of the people responsible for presenting the portal, developed over three years and which will incorporate content in Catalan, Spanish and English. The clinic’s managing director, Dr. Josep Maria Campistol, has declared that they hope it ...